All > Obsessive Compulsive Disorder > Ocd

Celecoxib for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates

Effectiveness

Safety

Obsessive-Compulsive Disorder+1 More

Celecoxib - Drug

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18 - 65

All Sexes

What conditions do you have?

Select

Eligibility

18 - 65

All Sexes

What conditions do you have?

Select

Study Summary

This trial will help researchers understand if anti-inflammatory drugs can be effective in treating OCD when used in addition to traditional medications.

Eligible Conditions

Obsessive-Compulsive Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Episcleral Celecoxib

Nabilone

Celecoxib

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Week 8

Baseline

TSPO Volume of Distribution assessed by PET imaging with [11C]ER-176

Week 8

CRP

MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel

PGE2

PGF2-alpha

Yale-Brown Obsessive Compulsive Scale

Trial Safety

Safety Progress

2 of 3

This is further along than 68% of similar trials

Other trials for Obsessive-Compulsive Disorder

Episcleral Celecoxib

Nabilone

Celecoxib

Side Effects for

Initial Dose Celecoxib 400 mg

5%Beta 2 microglobulin increased

3%Blood bilirubin increased

3%Beta-N-acetyl-D-glucosaminidase increased

2%Eczema

1%Somnolence

1%Post procedural haemorrhage

1%Presyncope

1%Hypoaesthesia facial

1%Blood urine present

1%Urobilin urine present

1%Blood phosphorus decreased

1%Blood creatine phosphokinase increased

1%White blood cell count increased

1%Rash

This histogram enumerates side effects from a completed 2010 Phase 2 trial (NCT01062113) in the Initial Dose Celecoxib 400 mg ARM group. Side effects include: Beta 2 microglobulin increased with 5%, Blood bilirubin increased with 3%, Beta-N-acetyl-D-glucosaminidase increased with 3%, Eczema with 2%, Somnolence with 1%.

Trial Design

1 Treatment Group

Celecoxib Treatment

1 of 1

Experimental Treatment

21 Total Participants · 1 Treatment Group

Primary Treatment: Celecoxib · No Placebo Group · Phase 2

Celecoxib Treatment

Drug

Experimental Group · 1 Intervention: Celecoxib · Intervention Types: Drug

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Celecoxib

FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: week 8

Who is running the clinical trial?

New York State Psychiatric InstituteLead Sponsor

455 Previous Clinical Trials

148,554 Total Patients Enrolled

23 Trials studying Obsessive-Compulsive Disorder

891 Patients Enrolled for Obsessive-Compulsive Disorder

Jeffrey Miller, M.D.Principal Investigator - New York State Psychiatric Institute

New York Presbyterian Hospital-Columbia Presbyterian Center, New York State Psychiatric Institute

Yale University School Of Medicine (Medical School)

Ny And Presby Hospital (Residency)

1 Previous Clinical Trials

25 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

You have the capacity to give informed consent.\n

About The Reviewer

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.